Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Review ArticleReview
Open Access

Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques

CONGGAI HUANG, XING LUO, SHAOHUA WANG, YU WAN, JIEQIONG WANG, XIAOQIN TANG, CHRISTOPH SCHATZ, HUILING ZHANG, JOHANNES HAYBAECK and ZHIHUI YANG
In Vivo January 2023, 37 (1) 11-21; DOI: https://doi.org/10.21873/invivo.13050
CONGGAI HUANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XING LUO
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHAOHUA WANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YU WAN
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JIEQIONG WANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XIAOQIN TANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHRISTOPH SCHATZ
2Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HUILING ZHANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOHANNES HAYBAECK
2Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria;
3Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: johannes.haybaeck@i-med.ac.at
ZHIHUI YANG
1Department of Pathology, The Affiliated Hospital of Southwest Medical University, Luzhou, P.R. China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yzhih73@126.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In recent years, the demand for cytopathological accurate diagnoses has increased as expanding minimally invasive procedures obtain materials from patients with advanced cancer for diagnostic, prognostic, and predictive purposes. However, inadequate knowledge of cytopathological technical procedures and ancillary techniques by clinicians remains the most common reason for the limited availability of cytopathology. The objectives of this review were to understand the technical procedures, ancillary techniques, and application and effectiveness of various types of tests in cytopathology. Each of the many ancillary technologies described in the literature has specific advantages and limitations and laboratories select one or more methods depending on their infrastructure and expertise to achieve the goal from initial screening of the disease to the final diagnosis of the cytopathology. This paper systematically reviews the development of cytopathology, summarizes the existing problems in cytopathology and the new progress of auxiliary examination, to provide a theoretical basis for the advanced development of cytopathological diagnostic technologies and to consolidate the minimally invasive and accurate diagnosis of cytopathologies for clinicians. Cytopathology offers many advantages over other clinical examinations, particularly for minimally invasive and accurate diagnosis.

Key Words:
  • Cytopathology
  • minimally invasive
  • accurate diagnosis
  • technical procedures
  • ancillary techniques
  • review

The emergence of cell theory, the discovery of physiology in the 17th century, the use of the microscope, and the establishment of pathological anatomy in the 18th century contributed to the development of cytopathology. Rudolf Virchow, a German scientist published the book Cytopathology, marking the birth of cytopathology in 1858 (1, 2). At the beginning of the 20th century, Yang Dawang founded China’s first cytology laboratories in the Department of Obstetrics and Gynecology of Peking Union Medical College and Beijing Hospital.

Cytopathology attributed the occurrence of the pathological state to cellular changes, which was an advance in pathology. Cytopathology is based on histology and is used to study the morphology and structure of tissue fragments, groups of cells and individual cells, as well as the relationship between cells and the tissue origin. It includes abscission cytology (AC) and fine needle aspiration cytology (FNA). AC is the examination of sputum, pleural and abdominal fluid, gastric juice, urine, cervical smear, and others. FNA requires a fine needle to absorb a relatively small number of cells from the lesion site, such as the lymph node, thyroid, breast, and lung. Cytopathological examination is simple, minimally invasive, and accurate, providing an important method for early diagnosis of malignant tumors. It is widely used in clinical and tumor investigation.

With the development of minimally invasive techniques, cytology is gradually becoming the main means of tissue diagnosis. Cytological diagnosis refers to the identification of cellular changes under a light microscope. Cytopathological diagnosis is a complex process, influenced by many factors. A large number of well-preserved cells on the smear is required for accurate diagnosis. In contrast, the absence of background information, poor images and blurred staining may lead to a misdiagnosis. Therefore, the methods and techniques of cytopathology are crucial for cytopathological diagnoses. When necessary, immunocytochemistry (ICC), electron microscopy, and molecular biology techniques are used to differentiate between reactive lesions and tumor changes (3).

Advances in cytopathological diagnosis methods and techniques have been reported previously (4-6). In this review, we focus on the technical advances in cytopathology, including AC and FNA. We describe the current state of ICC, flow cytometry (FCM), fluorescence in situ hybridization (FISH), DNA ploidy analysis, gene sequencing, artificial intelligence (AI), remote pathological diagnosis, deep learning, and digital storage for clinicians and cytopathologists.

Cytopathological Specimen Collection

Abscission cytology collection. Cancer cells are characterized by fast metabolism and a depletion in calcium and hyaluronidase, resulting in weakening of cell-cell connections and detachment of cells (7, 8). Adequate sample volume of AC, a representative cell collection and time-dependent smear fixation are requirements for a correct diagnosis.

Cervical exfoliation cytology is a method for cervical cancer screening, mainly consisting of cervical smear and thinPrep cytologic test (TCT) examination. The cervical smear contains pathological cells scraped with a specific curette to extract a relatively small number of cells. TCT is recommended to effectively improve the acquisition rate and diagnostic accuracy (9-11). SurePath and ThinPrep 2000 are two testing systems recommended by the FDA for cervical or vaginal usage (12, 13). The basic purpose of collecting cells is to increase the sampling of the complete transformation zone (TZ) and squamous columnar epithelial junction (SCJ), which is important for the pathogenesis of cervical cancer (14). Therefore, collecting cells from this region is crucial. Human papillomavirus (HPV) combined with TCT, P16/Ki-67, and E6/E7 provide effective markers for cancer screening (15, 16).

Non-gynecological cytology includes the innovation and improvement of various specimen collectors, washing fluid microporous membranes, and sputum releasers (17). Hemolytic substances and anticoagulants are added to thorax, ascites, and other body fluids containing high protein concentrations, followed by the preparation of a centrifugal precipitation smear (18). For urine and other low protein body fluids, sufficient cells can be obtained by centrifugal precipitation collector and microporous filtration membrane technology, increasing the positive rate (19).

Fine needle aspiration cytology specimen collection. FNA is a quick, economical, and minimally invasive method in which cells of suspicious lesions are repeatedly aspirated with a fine needle (the outer diameter of the needle is 0.6-0.9 mm). Then, the cytopathologist observes the samples under a microscope and issues a pathology report (20, 21). FNA can be used to puncture tumors and non-tumor lesions in almost all parts of the body, assuring a high positive rate and few false positives (22). Cytopathological diagnosis of superficial tumors, in the thyroid, breast, lymph nodes, subcutaneous masses, and deep tumors such as in the pancreas, retroperitoneum, liver, and kidney, is a very practical and convenient means of assessment (23, 24). Metastatic tumor is the most common cause of lymphadenopathy. Lymph node puncture can not only be used for the diagnosis of metastatic tumors, but also for the determination of the histological type and originating organ (25, 26).

The advent of cell chips has recently promoted the rapid development of FNA, enabling the use of few remaining cells in the needle after needle aspiration to perform high-throughput examination (27-30) with a wide usage of ultrasound-guided FNA (31-34). Fiber optic instruments and advanced imaging technology enabled FNA to obtain cells from almost all anatomical sites, which poses a challenge to the diagnostic level of cytologists (35, 36). Cell blocks (CB) are created by absorbing more specimens (Figure 1) by FNA for ICC and genetic testing (37, 38). CB offers versatility for diagnostic, prognostic, and predictive assays (39, 40).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Cell block preparation by fine needle aspiration. Fixed with 95% alcohol and paraffin embedded.

Fixation and staining. Cell fixation preserves cells close to their living state by artificial methods. The purpose of fixation is to prevent cell autolysis and conserving the original structure. Methods of cell fixation include wet fixation, dry fixation, liquid-based cytological fixation and other. Wet fixation is based on a fresh specimen smear combined with a fixative solution containing alcohol as the main component in the wet state. Dry fixation method is defined by smear naturally drying in air or by heat. For convenience, cell spray fixator can be used to cover the smear or it could be dropped directly onto the smear. 95% ethanol is the most used cell fixator. The smear is fixed for at least 15 min. Polyethylene glycol can be used as an alternative method for immobilization. Ether ethanol is comparable to 95% ethanol but is rarely used today due to toxic effects. Pure methanol, a fixative containing glacial acetic acid, anhydrous ethanol, acetone, and 4% neutral buffer formaldehyde solution are fixatives that can be used in cytopathology. Rapid alcohol fixation is recommended for Pap stain, which can significantly improve the interpretability of the results (41). Routine cervical cytology and pap smears originated in the 1940s and are accepted as the standard of gynecological care (42, 43).

Staining allows to highlight one part of the tissue and cells with different color intensities or alternatively use different colors for different parts, leading to different refractive indices and subsequently the display of various fine structures in the nucleus and cytoplasm more clearly. Cytological staining can be classified into three categories: conventional cytological staining, special cytological staining, and immunohistochemical staining. Common staining methods include HE, Pap, Diff-Quick, and Swiss staining. The main advantage of Pap staining is that it clearly shows the fine structure of the nucleus. The cytoplasm is bright and transparent, reflecting the change in the differentiation of the cytoplasm (44, 45). Diff-Quick staining is a fast staining method modified on the basis of Swiss staining. CellDetect® staining encompasses a dual color discrimination and a morphological analysis that has the potential to be one of the most effective methods for cervical cancer screening and early diagnosis (46). Quality control should be performed during routine dyeing (47). Many factors affect the accuracy of cytopathological examination in clinical work (Table I). Auxiliary examination or auxiliary combined examination is necessary.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Influencing factors of cytopathological examination.

Auxiliary Diagnostic

Immunocytochemistry. The recognition of benign and malignant cells in cytopathology is influenced by experience (Table II) and subjective deviations should be avoided. Molecular targeted therapy has been increasing in cancer therapy, especially with recurring and metastasizing tumors, and is considered the first choice of tumor treatment. For investigating multiple drug resistance, ICC is required and provides a way to investigate related gene and protein expression levels.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Morphological differences between benign and malignant cells.

ICC is a useful auxiliary diagnostic in cytopathology (48-50) and plays a key role in diagnosis, prognosis and in the identification of predictive markers (51-53). There are four methods of specimen preparation commonly used in ICC: direct smear, cytospin, paraffin embedded CB, and liquid-based thin layer preparation method. CB method is widely established (54-56). CB is essential for the future of cytology; more output could be achieved with less material and with a low degree of invasiveness. Strong evidence indicates that the combination of conventional cytology and CB improves the diagnostic accuracy of endosonography with FNA (EUS-FNA) (57). This approach should be implemented in general practice, especially where rapid onsite evaluation (ROSE) is not available. ICC staining is easy to operate, independent of cell morphology, uncomplicated to read, and can assist the identification of benign and malignant diseases (Figure 2). CB in combination with ICC is an effective supplement to conventional FNA smears, which can further improve the accuracy of cytopathological diagnosis and facilitate the selection of preoperative chemotherapy (58).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Immunocytochemistry of cell blocks.

ICC also has its own limitations: 1) No absolute specific antibody is available. 2) A considerable number of tumors lack specific antigen expression. 3) The same antigen can be expressed in multiple tumors. 4) Related antigens are absent in some tumors due to low differentiation. 5) In some cases, different antibody titers have different positive results. 6) Endogenous biotin can lead to false positives. 7) The results may be inconsistent between different laboratories. There are still many problems to be solved in quantitative analysis. Standard and correct technical operation in the immunization laboratory is the most important premise to ensure the correct application of ICC. Cytological specimens are mainly suitable for ICC, but proper optimization and strict quality control of high-quality stainings are fundamental (59).

Flow cytometry. With the rapid development of modern medicine, the proportion of diagnostics in clinical medicine is gradually increasing. The number of new diagnostic tools is also rising (60). To comprehensively analyze all kinds of independent diagnostic data to obtain useful information for clinical treatment is a major challenge to modern medicine. FCM is a technology used to conduct qualitative and quantitative analysis and sorting of single cells or biological particles one by one by multiple parameters in a state of rapid linear flow. As a technology platform, modern FCM was developed in the 1960s and 1970s. After about 40 years of development and improvement, FCM matured. It has been widely used in all aspects from basic research to clinical practice, covering the fields of cell biology, immunology, hematology, oncology, pharmacology, genetics, and clinical laboratory, playing a major part in various disciplines (61-64).

When carcinogenesis and precancerous lesions with malignant potential occur in the body, abnormal changes in DNA content may precede the current state of the tissue. FCM can accurately detect changes in DNA content by quantifying the DNA content of precancerous cells and determining the distribution of cell cycle according to the DNA distribution square diagram (65, 66). FCM has been successfully used to detect tumor cells in malignant effusions (67, 68). FCM combined with morphological analysis and ICC can overcome the individual limitations of each method and provide reliable results in a faster and more efficient manner, thereby improving the diagnosis and prognosis of breast cancer (69, 70). Intraoperative FCM can evaluate the margins of pancreatic cancer (71, 72). FCM detection of circulating tumor cells in portal venous blood is valuable in predicting postoperative metastasis of pancreatic or periampullary tumors (73). FCM can be used to diagnose lymphoma subtypes (74-76). Cerebrospinal fluid FCM can be used to screen for primary CNS lymphoma (77). FCM is developing towards high sensitivity, high speed, multiparameter measurement, and morphological information acquisition (78).

The limitations of FCM are the following: 1) The tissue structure cannot be addressed and some rare large cells are difficult to analyze. 2) Some cells are highly adhered and are difficult to extract by bone marrow puncture. 3) The prognostic value is lower than that of chromosome and gene analysis. 4) The equipment is expensive and requires professional and technical personnel to operate.

Fluorescence in situ hybridization. FISH is a technique that uses fluorescence-labeled specific nucleic acid probes to hybridize with corresponding target DNA or RNA molecules in cells. By observing fluorescence signals under a fluorescence microscope or confocal laser scanner, the morphology and distribution of cells or organelles that are stained after hybridization with specific probes, or the location of DNA regions or RNA molecules bound to fluorescent probes in chromosomes or other organelles could be resolved (79). CellDetect and FISH show equal value in diagnosing urothelial carcinoma, both are superior to conventional urine cytology (80). With the rapid scientific and technological development, more and more FISH probe markers have been identified, laying a solid foundation for the clinical application of FISH technology (81). Single fluorescence to multi-color fluorescence detection is possible, enabling the observation of cells in mitosis and also in interphase states.

The limitations of FISH are as follows: 1) The numerous steps are easy to cause signal loss and false negative results. 2) Only qualitative detection is possible, not quantitative. 3) RNA detection is only an indirect way to infer gene expression, inconsistent with protein level. 4) Hybridization cannot be achieved in 100% of cases. Shorter cDNA probes will result in a significant reduction in efficiency. 5) FISH is circumstantial and expensive.

Quantitative analysis of cell DNA ploidy. Automatic cell DNA quantitative analysis system allows the detection of DNA ploidy of genetic material in the nucleus, the investigation of the physiological state and pathological cell changes and allows the evaluation of cancer and precancerous lesions. The system can be used to analyze a variety of gynecological and non-gynecological clinical cytological specimens, including cervical exfoliation specimens, and can also assist the assessment of healing after tumor treatment (82).

At present, staining and image analysis techniques are used in the clinical context to measure the DNA content of solid tumors or puncture specimens. The techniques are applied on gastroscopy, esophagoscopy, tumor flushing fluid, urine and a small amount of tissue, to analyze the cell cycle state and tumor cell alloploidy, one of the most important indicators for differentiating benign and malignant tumors and determining early diagnosis of tumors (83). In parallel, DNA ploidy of tumor cells is analyzed, and the detection rate of DNA ploidy of tumor cells is closely related to clinical biological behaviors such as tumor diffusion and metastasis (84). However, a study has suggested that DNA ploidy alone is nonspecific and may not be a good tool for assessing oral cancer prognosis or metastatic progression (85). The DNA quantitative analysis system can detect cancer and precancerous lesions earlier than traditional cytology (86) and predict malignant transformation well. In addition, when it was combined with dysplasia grading, it gave the highest predictive value (87). In conclusion, the clinical application of tumor cell cycle and DNA ploidy analysis can be used as important indicators for early diagnosis of tumors.

Sequencing. Since Sanger (88) invented the first generation of gene sequencing technology, the technology has gradually become an effective method to analyze gene sequences and was used in the human Genome Project, to map the human genome (89). Fields of applications include disease diagnosis and drug development. Characterized by high throughput, next-generation sequencing (NGS) significantly reduces the cost of sequencing and advances gene sequencing from a single locus to the whole genome (90, 91). NGS can be used in cytopathology, including CBs, direct smears, liquid-based cytology and supernatants (91, 92). NGS is widely used in cancers (93). The third generation of sequencing technology, while maintaining the flux and speed of the second generation of sequencing, makes up for the deficiency of the second generation of sequencing regarding the read length.

Artificial intelligence. A new science named AI, researches and develops theories, methods, technologies, and application systems for simulating, extending, and expanding human intelligence (94). AI has been used as an important ancillary technique in the diagnosis of lung, breast, colon, and prostate cancers and has achieved good results (95-97). Advances in AI, image analysis, and deep learning are expanding the ways in which computational pathology can be applied to cytopathology (98). AI algorithms have a long history in the field of urine cytology and some of them have proven superior to human review results (99). Trained, tested, and validated models established in other areas of medicine are mature and can assist the diagnosis of cervical cell images (100). AI has its unique advantages in assisting pathological diagnosis of cervical cytology images. AI can significantly reduce the rate of misdiagnosis and missed diagnosis, classify cells more accurately, eliminate interference factors in a more robust manner, and reduce the single slide diagnosis time (101). The practical application of medical AI has been emphasized but the interpretability and the methods of operation have not been addressed. Helping cytopathologists to understand the benefits of the AI’s support and its limitations will contribute to its use in diagnostics and research (102).

Remote cytopathological diagnosis. Remote cytopathological diagnosis is a method of using telecommunication technology to transmit cytological images for tele-diagnosis, teaching, and research (103). Remote cytopathological diagnosis involves viewing cytological images on a computer screen rather than in a traditional bright field microscope. The requirements are an optical microscope, a high-resolution digital image acquisition instrument, a computer working platform, and a remote communication link. The accuracy of remote diagnosis is also related to the sampling area, image quality, diagnostic experience of the personnel, and expertise in viewing images on screens. Using the internet to transmit static digital images and selecting representative diagnostic areas from specimens is crucial (104). Currently, remote cytopathological diagnosis has started to be applied in routine diagnosis and education in Europe, the United States, and Japan (105). Camera improvements, software development and software operation on smart phones make smart phones effective tools for tele-pathology and tele-cytology (106). The digital slides generated by full slide scanners are sufficient to make cytological diagnoses and are comparable with physical slides observed by clinical pathologists at different professional levels (107). In cytopathological screening of cervical cancer, high-resolution digital cytopathological sections are very important for the interpretation of pathological cells. The study is expected to help to increase cytopathological screening in remote and poor areas where high-end imaging equipment is not available (108).

Deep learning in cytopathology. In recent decades, the great advances in image processing and speech recognition based on deep learning have greatly promoted the development of quantitative analysis and automatic detection of pathological images (109). Deep learning is especially useful for very large and unstructured data sets and is excellent at handling complex problems such as image classification. Furthermore, the applications in cytopathology are increasing. Zhang et al. (110) developed a deep convolutional neural network (DCNN) system to segment cell clusters and to recognize the cytopathological sections of cancer cell clusters on images. The DCNN system is feasible and robust in identifying pancreatic cancer cell clusters. Deep learning system can screen urothelial carcinoma cells more accurately than traditional cytology approaches and includes an evaluation of the malignant potential of tumors (111). Deep learning systems in cytopathological screening support urologists to develop treatment strategies to benefit the patients. Deep learning models are resistant to changes in the aspect ratio of cells in cervical cytopathological images (112).

Digital storage. Recent advances in digital pathology have decreased the effort and increased the availability of pathology in disease diagnosis, especially in tumor diagnosis. However, despite the potential to include low-cost diagnostics and viable telemedicine, digital pathology is not yet available due to expensive storage, data security requirements, and network bandwidth constraints for streaming high-resolution images and related metadata (113).

Conclusion

In conclusion, cytopathology has developed rapidly in recent years and achieved significant results. Moreover, many research methods using new technologies have emerged, providing more methods for the development of cytopathology and the diagnosis and treatment of clinical diseases. The quality control of cytopathology is an important mechanism to improve the diagnosis of cytopathology and the development of a quality control system will further promote the development of cytopathology. Cytopathology technology is becoming more and more automated and standardized. Although ancillary techniques are fundamental for improving the accuracy and census rate, their high cost is still a major issue. How to better learn and use these technologies is key for us.

Acknowledgements

This work was financially supported by the project of the department of science and Technology, Sichuan province (No.22ZDYF3780).

Footnotes

  • Authors’ Contributions

    Conggai Huang reviewed and synthesized the relevant information and was the primary author of the review article. Xing Luo and Shaohua Wang reviewed and synthesized the relevant information. Yu Wan and Jieqiong Wang collected the data. Xiaoqin Tang and Huiling Zhang contributed figures and discussion of the review article. Johannes Haybaeck and Zhihui Yang made substantial contributions to the conception, drafting, and revision of the article. All Authors contributed to the article and approved the submitted version.

  • Conflicts of Interest

    The Authors have no conflicts of interest to declare in relation to this study.

  • Received November 8, 2022.
  • Revision received December 15, 2022.
  • Accepted December 16, 2022.
  • Copyright © 2023, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (https://creativecommons.org/licenses/by-nc-nd/4.0).

References

  1. ↵
    1. de Gouveia RH,
    2. Gulczynski J,
    3. Canzonieri V,
    4. Nesi G and History of Pathology Working Group of the European Society of Pathology
    : Rudolf Virchow: 200th birth anniversary. Virchows Arch 479(6): 1063-1065, 2021. PMID: 34910234. DOI: 10.1007/s00428-021-03252-w
    OpenUrlCrossRefPubMed
  2. ↵
    1. Goschler C
    : [Pathology and modernity: a look back at Rudolf Virchow on the occasion of his 200th birthday]. Pathologe 42(6): 617-619, 2021. PMID: 34622295. DOI: 10.1007/s00292-021-01005-9
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bishop JA
    : Immunohistochemistry surrogates for molecular alterations: A new paradigm in salivary gland tumor cytopathology? Cancer Cytopathol 129(2): 102-103, 2021. PMID: 32809250. DOI: 10.1002/cncy.22337
    OpenUrlCrossRefPubMed
  4. ↵
    1. Tobias AHG,
    2. Vitalino AC,
    3. Rezende MT,
    4. Oliveira RRR,
    5. Coura-Vital W,
    6. Amaral RG and
    7. Carneiro CM
    : Performance of rapid prescreening and 100% rapid review as internal quality control methods for cervical cytopathology. Cytopathology 29(5): 428-435, 2018. PMID: 29904955. DOI: 10.1111/cyt.12599
    OpenUrlCrossRefPubMed
    1. Vaickus LJ,
    2. Suriawinata AA,
    3. Wei JW and
    4. Liu X
    : Automating the Paris System for urine cytopathology-A hybrid deep-learning and morphometric approach. Cancer Cytopathol 127(2): 98-115, 2019. PMID: 30702803. DOI: 10.1002/cncy.22099
    OpenUrlCrossRefPubMed
  5. ↵
    1. Srebotnik Kirbiš I,
    2. Rodrigues Roque R,
    3. Bongiovanni M,
    4. Strojan Fležar M and
    5. Cochand-Priollet B
    : Immunocytochemistry practices in European cytopathology laboratories-Review of European Federation of Cytology Societies (EFCS) online survey results with best practice recommendations. Cancer Cytopathol 128(10): 757-766, 2020. PMID: 32598103. DOI: 10.1002/cncy.22311
    OpenUrlCrossRefPubMed
  6. ↵
    1. Fatima K,
    2. Masood N,
    3. Ahmad Wani Z,
    4. Meena A and
    5. Luqman S
    : Neomenthol prevents the proliferation of skin cancer cells by restraining tubulin polymerization and hyaluronidase activity. J Adv Res 34: 93-107, 2021. PMID: 35024183. DOI: 10.1016/j.jare.2021.06.003
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kim K,
    2. Choi H,
    3. Choi ES,
    4. Park MH and
    5. Ryu JH
    : Hyaluronic acid-coated nanomedicine for targeted cancer therapy. Pharmaceutics 11(7): 301, 2019. PMID: 31262049. DOI: 10.3390/pharmaceutics11070301
    OpenUrlCrossRefPubMed
  8. ↵
    1. Tan X,
    2. Li K,
    3. Zhang J,
    4. Wang W,
    5. Wu B,
    6. Wu J,
    7. Li X and
    8. Huang X
    : Automatic model for cervical cancer screening based on convolutional neural network: a retrospective, multicohort, multicenter study. Cancer Cell Int 21(1): 35, 2021. PMID: 33413391. DOI: 10.1186/s12935-020-01742-6
    OpenUrlCrossRefPubMed
    1. Naizhaer G,
    2. Yuan J,
    3. Mijiti P,
    4. Aierken K,
    5. Abulizi G and
    6. Qiao Y
    : Evaluation of multiple screening methods for cervical cancers in rural areas of Xinjiang, China. Medicine (Baltimore) 99(6): e19135, 2020. PMID: 32028440. DOI: 10.1097/MD.0000000000019135
    OpenUrlCrossRefPubMed
  9. ↵
    1. Husaiyin S,
    2. Jiao Z,
    3. Yimamu K,
    4. Maisaidi R,
    5. Han L and
    6. Niyazi M
    : ThinPrep cytology combined with HPV detection in the diagnosis of cervical lesions in 1622 patients. PLoS One 16(12): e0260915, 2021. PMID: 34855928. DOI: 10.1371/journal.pone.0260915
    OpenUrlCrossRefPubMed
  10. ↵
    1. Rozemeijer K,
    2. Penning C,
    3. Siebers AG,
    4. Naber SK,
    5. Matthijsse SM,
    6. van Ballegooijen M,
    7. van Kemenade FJ and
    8. de Kok IM
    : Comparing SurePath, ThinPrep, and conventional cytology as primary test method: SurePath is associated with increased CIN II+ detection rates. Cancer Causes Control 27(1): 15-25, 2016. PMID: 26458884. DOI: 10.1007/s10552-015-0678-1
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rozemeijer K,
    2. Naber SK,
    3. Penning C,
    4. Overbeek LI,
    5. Looman CW,
    6. de Kok IM,
    7. Matthijsse SM,
    8. Rebolj M,
    9. van Kemenade FJ and
    10. van Ballegooijen M
    : Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study. BMJ 356: j504, 2017. PMID: 28196844. DOI: 10.1136/bmj.j504
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Kamal M
    : Pap smear collection and preparation: key points. Cytojournal 19: 24, 2022. PMID: 35510105. DOI: 10.25259/CMAS_03_05_2021
    OpenUrlCrossRefPubMed
  13. ↵
    1. Benevolo M,
    2. Mancuso P,
    3. Allia E,
    4. Gustinucci D,
    5. Bulletti S,
    6. Cesarini E,
    7. Carozzi FM,
    8. Confortini M,
    9. Bisanzi S,
    10. Rubino T,
    11. Rollo F,
    12. Marchi N,
    13. Farruggio A,
    14. Pusiol T,
    15. Venturelli F,
    16. Giorgi Rossi P and New Technologies for Cervical Cancer 2 (NTCC2) Working Group
    : Determinants of p16/Ki-67 adequacy and positivity in HPV-positive women from a screening population. Cancer Cytopathol 129(5): 383-393, 2021. PMID: 33142029. DOI: 10.1002/cncy.22385
    OpenUrlCrossRefPubMed
  14. ↵
    1. Giorgi Rossi P,
    2. Carozzi F,
    3. Ronco G,
    4. Allia E,
    5. Bisanzi S,
    6. Gillio-Tos A,
    7. De Marco L,
    8. Rizzolo R,
    9. Gustinucci D,
    10. Del Mistro A,
    11. Frayle H,
    12. Confortini M,
    13. Iossa A,
    14. Cesarini E,
    15. Bulletti S,
    16. Passamonti B,
    17. Gori S,
    18. Toniolo L,
    19. Barca A,
    20. Bonvicini L,
    21. Mancuso P,
    22. Venturelli F,
    23. Benevolo M and the New Technology for Cervical Cancer 2 Working Group
    : p16/ki67 and E6/E7 mRNA accuracy and prognostic value in triaging HPV DNA-positive women. J Natl Cancer Inst 113(3): 292-300, 2021. PMID: 32745170. DOI: 10.1093/jnci/djaa105
    OpenUrlCrossRefPubMed
  15. ↵
    1. Ikeda K,
    2. Sato S,
    3. Chigira H,
    4. Shibuki Y and
    5. Hiraoka N
    : Characterizing the effect of automated cell sorting solutions on cytomorphological changes. Acta Cytol 64(3): 232-240, 2020. PMID: 31234180. DOI: 10.1159/000500769
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ikeda K,
    2. Oboshi W,
    3. Hashimoto Y,
    4. Komene T,
    5. Yamaguchi Y,
    6. Sato S,
    7. Maruyama S,
    8. Furukawa N,
    9. Sakabe N and
    10. Nagata K
    : Characterizing the effect of processing technique and solution type on cytomorphology using liquid-based cytology. Acta Cytol 66(1): 55-60, 2022. PMID: 34644702. DOI: 10.1159/000519335
    OpenUrlCrossRefPubMed
  17. ↵
    1. Munch MM,
    2. Chambers LC,
    3. Manhart LE,
    4. Domogala D,
    5. Lopez A,
    6. Fredricks DN and
    7. Srinivasan S
    : Optimizing bacterial DNA extraction in urine. PLoS One 14(9): e0222962, 2019. PMID: 31550285. DOI: 10.1371/journal.pone.0222962
    OpenUrlCrossRefPubMed
  18. ↵
    1. Zhang Y,
    2. Renberg S,
    3. Papakonstantinou A and
    4. Haglund de Flon F
    : Diagnosing gastrointestinal stromal tumors: The utility of fine-needle aspiration cytology versus biopsy. Cancer Med 11(14): 2729-2734, 2022. PMID: 35301817. DOI: 10.1002/cam4.4630
    OpenUrlCrossRefPubMed
  19. ↵
    1. El Chamieh C,
    2. Vielh P and
    3. Chevret S
    : Statistical methods for evaluating the fine needle aspiration cytology procedure in breast cancer diagnosis. BMC Med Res Methodol 22(1): 40, 2022. PMID: 35125097. DOI: 10.1186/s12874-022-01506-y
    OpenUrlCrossRefPubMed
  20. ↵
    1. Erdogan-Durmus S
    : Diagnostic value of liquid-based cytology test in intrathoracic lymph nodes and lung lesions sampled by endobronchial ultrasonography-transbronchial needle aspiration. Diagn Cytopathol 49(12): 1251-1256, 2021. PMID: 34709736. DOI: 10.1002/dc.24898
    OpenUrlCrossRefPubMed
  21. ↵
    1. Budhwar A,
    2. Kataria SP,
    3. Kumar S,
    4. Singh G,
    5. Kaushik N and
    6. Sen R
    : Fine needle aspiration cytology of cervical lymph nodes: Comparison of liquid based cytology (SurePath) and conventional preparation. Diagn Cytopathol 49(1): 18-24, 2021. PMID: 32841545. DOI: 10.1002/dc.24589
    OpenUrlCrossRefPubMed
  22. ↵
    1. Mais DD,
    2. Crothers BA,
    3. Davey DD,
    4. Natale KE,
    5. Nayar R,
    6. Souers RJ,
    7. Blond BJ,
    8. Hackman S and
    9. Tworek JA
    : Trends in thyroid fine-needle aspiration cytology practices: Results from a College of American Pathologists 2016 practice survey. Arch Pathol Lab Med 143(11): 1364-1372, 2019. PMID: 31100017. DOI: 10.5858/arpa.2018-0429-CP
    OpenUrlCrossRefPubMed
  23. ↵
    1. Ronchi A,
    2. Caputo A,
    3. Pagliuca F,
    4. Montella M,
    5. Marino FZ,
    6. Zeppa P,
    7. Franco R and
    8. Cozzolino I
    : Lymph node fine needle aspiration cytology (FNAC) in paediatric patients: Why not? Diagnostic accuracy of FNAC in a series of heterogeneous paediatric lymphadenopathies. Pathol Res Pract 217: 153294, 2021. PMID: 33290901. DOI: 10.1016/j.prp.2020.153294
    OpenUrlCrossRefPubMed
  24. ↵
    1. Tanaka E,
    2. Oda N,
    3. Kobayashi S,
    4. Ogawa T,
    5. Mitani R,
    6. Nawa T,
    7. Takata I,
    8. Ueki T and
    9. Okada H
    : Mediastinal lymph node metastasis of esophageal cancer with esophageal stenosis diagnosed via transesophageal endoscopic ultrasound with bronchoscope-guided fine-needle aspiration. Intern Med 61(7): 1007-1010, 2022. PMID: 34511572. DOI: 10.2169/internalmedicine.8214-21
    OpenUrlCrossRefPubMed
  25. ↵
    1. Sekita-Hatakeyama Y,
    2. Fujii T,
    3. Nishikawa T,
    4. Mitoro A,
    5. Sawai M,
    6. Itami H,
    7. Morita K,
    8. Uchiyama T,
    9. Takeda M,
    10. Sho M,
    11. Yoshiji H,
    12. Hatakeyama K and
    13. Ohbayashi C
    : Evaluation and diagnostic value of next-generation sequencing analysis of residual liquid-based cytology specimens of pancreatic masses. Cancer Cytopathol 130(3): 202-214, 2022. PMID: 34665935. DOI: 10.1002/cncy.22525
    OpenUrlCrossRefPubMed
    1. Zhao JJ,
    2. Chan HP,
    3. Soon YY,
    4. Huang Y,
    5. Soo RA and
    6. Kee ACL
    : A systematic review and meta-analysis of the adequacy of endobronchial ultrasound transbronchial needle aspiration for next-generation sequencing in patients with non-small cell lung cancer. Lung Cancer 166: 17-26, 2022. PMID: 35151114. DOI: 10.1016/j.lungcan.2022.01.018
    OpenUrlCrossRefPubMed
    1. Carrara S,
    2. Soldà G,
    3. Di Leo M,
    4. Rahal D,
    5. Peano C,
    6. Giunta M,
    7. Lamonaca L,
    8. Auriemma F,
    9. Anderloni A,
    10. Fugazza A,
    11. Maselli R,
    12. Malesci A,
    13. Laghi L and
    14. Repici A
    : Side-by-side comparison of next-generation sequencing, cytology, and histology in diagnosing locally advanced pancreatic adenocarcinoma. Gastrointest Endosc 93(3): 597-604.e5, 2021. PMID: 32640200. DOI: 10.1016/j.gie.2020.06.069
    OpenUrlCrossRefPubMed
  26. ↵
    1. Freiberger SN,
    2. Brada M,
    3. Fritz C,
    4. Höller S,
    5. Vogetseder A,
    6. Horcic M,
    7. Bihl M,
    8. Michal M,
    9. Lanzer M,
    10. Wartenberg M,
    11. Borner U,
    12. Bode PK,
    13. Broglie MA,
    14. Rordorf T,
    15. Morand GB and
    16. Rupp NJ
    : SalvGlandDx - a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 23(5): 473-487, 2021. PMID: 33878706. DOI: 10.1016/j.neo.2021.03.008
    OpenUrlCrossRefPubMed
  27. ↵
    1. Sydney GI,
    2. Ioakim KJ,
    3. Michaelides C,
    4. Sepsa A,
    5. Sopaki-Valalaki A,
    6. Tsiotos GG,
    7. Theocharis S,
    8. Salla C and
    9. Nikas I
    : EUS-FNA diagnosis of pancreatic serous cystadenoma with the aid of cell blocks and α-inhibin immunochemistry: A case series. Diagn Cytopathol 48(3): 239-243, 2020. PMID: 31785091. DOI: 10.1002/dc.24348
    OpenUrlCrossRefPubMed
    1. Nikas IP,
    2. Sepsa A,
    3. Kleidaradaki E and
    4. Salla C
    : EUS-FNA diagnosis of a metastatic adult granulosa cell tumor in the stomach. Lab Med 53(5): 533-536, 2022. PMID: 35394548. DOI: 10.1093/labmed/lmac024
    OpenUrlCrossRefPubMed
    1. Cho IR,
    2. Jeong SH,
    3. Kang H,
    4. Kim EJ,
    5. Kim YS and
    6. Cho JH
    : Comparison of contrast-enhanced versus conventional EUS-guided FNA/fine-needle biopsy in diagnosis of solid pancreatic lesions: a randomized controlled trial. Gastrointest Endosc 94(2): 303-310, 2021. PMID: 33497643. DOI: 10.1016/j.gie.2021.01.018
    OpenUrlCrossRefPubMed
  28. ↵
    1. van Riet PA,
    2. Quispel R,
    3. Cahen DL,
    4. Erler NS,
    5. Snijders-Kruisbergen MC,
    6. Van Loenen P,
    7. Poley JW,
    8. van Driel LMJW,
    9. Mulder SA,
    10. Veldt BJ,
    11. Leeuwenburgh I,
    12. Anten MGF,
    13. Honkoop P,
    14. Thijssen AY,
    15. Hol L,
    16. Hadithi M,
    17. Fitzpatrick CE,
    18. Schot I,
    19. Bergmann JF,
    20. Bhalla A,
    21. Bruno MJ and
    22. Biermann K
    : Optimizing cytological specimens of EUS-FNA of solid pancreatic lesions: A pilot study to the effect of a smear preparation training for endoscopy personnel on sample quality and accuracy. Diagn Cytopathol 49(2): 295-302, 2021. PMID: 33098625. DOI: 10.1002/dc.24645
    OpenUrlCrossRefPubMed
  29. ↵
    1. Zhu H,
    2. Jiang F,
    3. Zhu J,
    4. Du Y,
    5. Jin Z and
    6. Li Z
    : Assessment of morbidity and mortality associated with endoscopic ultrasound-guided fine-needle aspiration for pancreatic cystic lesions: A systematic review and meta-analysis. Dig Endosc 29(6): 667-675, 2017. PMID: 28218999. DOI: 10.1111/den.12851
    OpenUrlCrossRefPubMed
  30. ↵
    1. Stegehuis PL,
    2. Boogerd LS,
    3. Inderson A,
    4. Veenendaal RA,
    5. van Gerven P,
    6. Bonsing BA,
    7. Sven Mieog J,
    8. Amelink A,
    9. Veselic M,
    10. Morreau H,
    11. van de Velde CJ,
    12. Lelieveldt BP,
    13. Dijkstra J,
    14. Robinson DJ and
    15. Vahrmeijer AL
    : Toward optical guidance during endoscopic ultrasound-guided fine needle aspirations of pancreatic masses using single fiber reflectance spectroscopy: a feasibility study. J Biomed Opt 22(2): 24001, 2017. PMID: 28170030. DOI: 10.1117/1.JBO.22.2.024001
    OpenUrlCrossRefPubMed
  31. ↵
    1. Chen L,
    2. Jing H,
    3. Gong Y,
    4. Tam AL,
    5. Stewart J,
    6. Staerkel G and
    7. Guo M
    : Diagnostic efficacy and molecular testing by combined fine-needle aspiration and core needle biopsy in patients with a lung nodule. Cancer Cytopathol 128(3): 201-206, 2020. PMID: 31913583. DOI: 10.1002/cncy.22234
    OpenUrlCrossRefPubMed
  32. ↵
    1. Singh P,
    2. Kumar P,
    3. Rohilla M,
    4. Gupta P,
    5. Gupta N,
    6. Dey P,
    7. Srinivasan R,
    8. Rajwanshi A and
    9. Nada R
    : Fine needle aspiration cytology with the aid of immunocytochemistry on cell-block confirms the diagnosis of solid pseudopapillary neoplasm of the pancreas. Cytopathology 32(1): 57-64, 2021. PMID: 32319130. DOI: 10.1111/cyt.12838
    OpenUrlCrossRefPubMed
  33. ↵
    1. Sale MS,
    2. Kulkarni VV,
    3. Kulkarni PV and
    4. Patil CA
    : Efficacy of modified cell block cytology compared to fine needle aspiration cytology for diagnostic oral cytopathology. Biotech Histochem 96(3): 197-201, 2021. PMID: 32552083. DOI: 10.1080/10520295.2020.1780314
    OpenUrlCrossRefPubMed
  34. ↵
    1. McGoogan E,
    2. Colgan TJ,
    3. Ramzy I,
    4. Cochand-Priollet B,
    5. Davey DD,
    6. Grohs HK,
    7. Gurley AM,
    8. Husain OA,
    9. Hutchinson ML,
    10. Knesel EA Jr.,
    11. Linder J,
    12. Mango LJ,
    13. Mitchell H,
    14. Peebles A,
    15. Reith A,
    16. Robinowitz M,
    17. Sauer T,
    18. Shida S,
    19. Solomon D,
    20. Topalidis T,
    21. Wilbur DC and
    22. Yamauchi K
    : Cell preparation methods and criteria for sample adequacy. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Acta Cytol 42(1): 25-32, 1998. PMID: 9479321. DOI: 10.1159/000331532
    OpenUrlCrossRefPubMed
  35. ↵
    1. Swailes AL,
    2. Hossler CE and
    3. Kesterson JP
    : Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day. Gynecol Oncol 154(1): 3-7, 2019. PMID: 30995961. DOI: 10.1016/j.ygyno.2019.04.004
    OpenUrlCrossRefPubMed
  36. ↵
    1. Kamal M and
    2. Topiwala F
    : Nonneoplastic cervical cytology. Cytojournal 19: 25, 2022. PMID: 35510107. DOI: 10.25259/CMAS_03_06_2021
    OpenUrlCrossRefPubMed
  37. ↵
    1. Uppada SB,
    2. Madduri LSV,
    3. Singu S,
    4. Lawson B,
    5. Bauer L,
    6. Freifeld A,
    7. Bhatt VR and
    8. Byrareddy SN
    : Modified Papanicolaou staining for oral swab samples stored long term. Biotech Histochem 96(5): 359-363, 2021. PMID: 32820964. DOI: 10.1080/10520295.2020.1804075
    OpenUrlCrossRefPubMed
  38. ↵
    1. Pote A,
    2. Boghenco O and
    3. Marques-Ramos A
    : Molecular analysis of H&E- and Papanicolau-stained samples-systematic review. Histochem Cell Biol 154(1): 7-20, 2020. PMID: 32372108. DOI: 10.1007/s00418-020-01882-w
    OpenUrlCrossRefPubMed
  39. ↵
    1. He S,
    2. Wang GL,
    3. Zhu YY,
    4. Wu MH,
    5. Ji ZG,
    6. Seng J,
    7. Ji Y,
    8. Zhou JM and
    9. Chen L
    : Application of the CellDetect® staining technique in diagnosis of human cervical cancer. Gynecol Oncol 132(2): 383-388, 2014. PMID: 24361533. DOI: 10.1016/j.ygyno.2013.12.016
    OpenUrlCrossRefPubMed
  40. ↵
    1. Chandra S,
    2. Chandra H,
    3. Kusum A and
    4. Singh Gaur D
    : Study of the pre-analytical phase of an ISO 15189: 2012-certified cytopathology laboratory: a 5-year institutional experience. Acta Cytol 63(1): 56-62, 2019. PMID: 30566946. DOI: 10.1159/000494567
    OpenUrlCrossRefPubMed
  41. ↵
    1. Kanber Y,
    2. Pusztaszeri M and
    3. Auger M
    : Immunocytochemistry for diagnostic cytopathology-A practical guide. Cytopathology 32(5): 562-587, 2021. PMID: 34033162. DOI: 10.1111/cyt.12993
    OpenUrlCrossRefPubMed
  42. ↵
    1. Kapoor D,
    2. Handa U,
    3. Kundu R and
    4. Das A
    : Diagnostic utility of p16 immunocytochemistry in metastatic cervical lymph nodes in head and neck cancers. Diagn Cytopathol 49(4): 469-474, 2021. PMID: 33428334. DOI: 10.1002/dc.24696
    OpenUrlCrossRefPubMed
    1. Kundu R,
    2. Singh B and
    3. Dey P
    : Cytology coupled with immunocytochemistry identifies Merkel cell carcinoma: A rare intruder in the cerebrospinal fluid. Cytopathology 33(4): 530-533, 2022. PMID: 35416339. DOI: 10.1111/cyt.13127
    OpenUrlCrossRefPubMed
  43. ↵
    1. Metovic J,
    2. Righi L,
    3. Delsedime L,
    4. Volante M and
    5. Papotti M
    : Role of immunocytochemistry in the cytological diagnosis of pulmonary tumors. Acta Cytol 64(1-2): 16-29, 2020. PMID: 30878997. DOI: 10.1159/000496030
    OpenUrlCrossRefPubMed
  44. ↵
    1. VanderLaan PA
    : Non-small cell lung cancer predictive biomarker testing via immunocytochemistry: Ways of future past? Cancer Cytopathol 127(5): 278-280, 2019. PMID: 31050221. DOI: 10.1002/cncy.22138
    OpenUrlCrossRefPubMed
    1. Iwahashi H,
    2. Miyamoto M,
    3. Minabe S,
    4. Hada T,
    5. Sakamoto T,
    6. Ishibashi H,
    7. Kakimoto S,
    8. Matsuura H,
    9. Suzuki R,
    10. Matsukuma S,
    11. Tsuda H and
    12. Takano M
    : Diagnostic efficacy of ascites cell block for ovarian clear cell carcinoma. Diagn Cytopathol 49(6): 735-742, 2021. PMID: 33675673. DOI: 10.1002/dc.24734
    OpenUrlCrossRefPubMed
  45. ↵
    1. Zaidi A,
    2. Srinivasan R,
    3. Rajwanshi A,
    4. Dey P and
    5. Gupta K
    : Ameloblastoma diagnosis by fine-needle aspiration cytology supplemented by cell block samples. Diagn Cytopathol 49(3): E93-E98, 2021. PMID: 32841532. DOI: 10.1002/dc.24600
    OpenUrlCrossRefPubMed
  46. ↵
    1. Saha BK and
    2. Bonnier A
    : Cell block examination of pleural fluid, an underused and overlooked method for evaluation of malignant pleural effusion. Am J Med Sci 363(6): 556-557, 2022. PMID: 34666061. DOI: 10.1016/j.amjms.2021.10.005
    OpenUrlCrossRefPubMed
    1. Alrajjal A,
    2. Choudhury M,
    3. Yang J and
    4. Gabali A
    : Cell-blocks and hematolymphoid lesions. Cytojournal 18: 7, 2021. PMID: 34221096. DOI: 10.25259/Cytojournal_10_2021
    OpenUrlCrossRefPubMed
  47. ↵
    1. Pausawasdi N,
    2. Hongsrisuwan P,
    3. Chalermwai WV,
    4. Butt AS,
    5. Maipang K and
    6. Charatchareonwitthaya P
    : The diagnostic performance of combined conventional cytology with smears and cell block preparation obtained from endoscopic ultrasound-guided fine needle aspiration for intra-abdominal mass lesions. PLoS One 17(3): e0263982, 2022. PMID: 35320282. DOI: 10.1371/journal.pone.0263982
    OpenUrlCrossRefPubMed
  48. ↵
    1. Kanjilal B,
    2. Das RN,
    3. Chatterjee U,
    4. Sengupta M,
    5. Sarkar R and
    6. Saha K
    : Utility of cell block preparation in diagnosis of paediatric abdominal neoplasms. Diagn Cytopathol 49(3): 404-411, 2021. PMID: 33226199. DOI: 10.1002/dc.24670
    OpenUrlCrossRefPubMed
  49. ↵
    1. Jain D,
    2. Nambirajan A,
    3. Borczuk A,
    4. Chen G,
    5. Minami Y,
    6. Moreira AL,
    7. Motoi N,
    8. Papotti M,
    9. Rekhtman N,
    10. Russell PA,
    11. Savic Prince S,
    12. Yatabe Y,
    13. Bubendorf L and IASLC Pathology Committee
    : Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathol 127(5): 325-339, 2019. PMID: 31050216. DOI: 10.1002/cncy.22137
    OpenUrlCrossRefPubMed
  50. ↵
    1. Uno N,
    2. Kaku N,
    3. Morinaga Y,
    4. Hasegawa H and
    5. Yanagihara K
    : Flow cytometry assay for the detection of single-copy DNA in human lymphocytes. Nucleic Acids Res 48(15): e86, 2020. PMID: 32544240. DOI: 10.1093/nar/gkaa515
    OpenUrlCrossRefPubMed
  51. ↵
    1. Choy B,
    2. Venkataraman G,
    3. Biernacka A,
    4. Lastra RR,
    5. Mueller J,
    6. Setia N,
    7. Reeves W and
    8. Antic T
    : Correlation of cytopathology with flow cytometry and histopathology for the diagnosis of hematologic malignancies in young adults presenting with cervical lymphadenopathy. Diagn Cytopathol 47(6): 579-583, 2019. PMID: 30794347. DOI: 10.1002/dc.24157
    OpenUrlCrossRefPubMed
  52. ↵
    1. Willner J,
    2. Zhou F and
    3. Moreira AL
    : Diagnostic challenges in the cytology of thymic epithelial neoplasms. Cancers (Basel) 14(8): 301, 2022. PMID: 35454918. DOI: 10.3390/cancers14082013
    OpenUrlCrossRefPubMed
    1. Lo Gullo R,
    2. Cloutier Lambert C,
    3. Lin O,
    4. Jochelson MS and
    5. D’Alessio D
    : Yield of flow cytometry in addition to cytology for lymph node sampling in patients with incidental axillary adenopathy without a concurrent diagnosis of primary breast malignancy. Breast Cancer Res Treat 191(3): 677-683, 2022. PMID: 35013915. DOI: 10.1007/s10549-021-06473-4
    OpenUrlCrossRefPubMed
    1. Cattin S,
    2. Fellay B,
    3. Calderoni A,
    4. Christinat A,
    5. Negretti L,
    6. Biggiogero M,
    7. Badellino A,
    8. Schneider AL,
    9. Tsoutsou P,
    10. Pellanda AF and
    11. Rüegg C
    : Circulating immune cell populations related to primary breast cancer, surgical removal, and radiotherapy revealed by flow cytometry analysis. Breast Cancer Res 23(1): 64, 2021. PMID: 34090509. DOI: 10.1186/s13058-021-01441-8
    OpenUrlCrossRefPubMed
  53. ↵
    1. Nair A and
    2. Manohar SM
    : A flow cytometric journey into cell cycle analysis. Bioanalysis 13(21): 1627-1644, 2021. PMID: 34601886. DOI: 10.4155/bio-2021-0071
    OpenUrlCrossRefPubMed
  54. ↵
    1. Kusama H,
    2. Shimoda M,
    3. Miyake T,
    4. Tanei T,
    5. Kagara N,
    6. Naoi Y,
    7. Shimazu K,
    8. Kim SJ and
    9. Noguchi S
    : Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues. Breast Cancer Res Treat 176(1): 75-85, 2019. PMID: 30949799. DOI: 10.1007/s10549-019-05222-y
    OpenUrlCrossRefPubMed
  55. ↵
    1. Takahashi K,
    2. Kurashina K,
    3. Saito S,
    4. Kanamaru R,
    5. Ohzawa H,
    6. Yamaguchi H,
    7. Miyato H,
    8. Hosoya Y,
    9. Lefor AK,
    10. Sata N and
    11. Kitayama J
    : Flow cytometry-based analysis of tumor-leukocyte ratios in peritoneal fluid from patients with advanced gastric cancer. Cytometry B Clin Cytom 100(6): 666-675, 2021. PMID: 33277773. DOI: 10.1002/cyto.b.21978
    OpenUrlCrossRefPubMed
  56. ↵
    1. Rikkert LG,
    2. de Rond L,
    3. van Dam A,
    4. van Leeuwen TG,
    5. Coumans FAW,
    6. de Reijke TM,
    7. Terstappen LWMM and
    8. Nieuwland R
    : Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging. PLoS One 15(6): e0233443, 2020. PMID: 32497056. DOI: 10.1371/journal.pone.0233443
    OpenUrlCrossRefPubMed
  57. ↵
    1. Wopereis S,
    2. Walter LO,
    3. Vieira DSC,
    4. Ribeiro AAB,
    5. Fernandes BL,
    6. Wilkens RS and
    7. Santos-Silva MC
    : Evaluation of ER, PR and HER2 markers by flow cytometry for breast cancer diagnosis and prognosis. Clin Chim Acta 523: 504-512, 2021. PMID: 34762935. DOI: 10.1016/j.cca.2021.11.005
    OpenUrlCrossRefPubMed
  58. ↵
    1. Markopoulos GS,
    2. Harissis H,
    3. Andreou M,
    4. Alexiou GA and
    5. Vartholomatos G
    : Intraoperative flow cytometry for invasive breast cancer conserving surgery: A new alternative or adjunct to cavity shaving technique? Surg Oncol 42: 101712, 2022. PMID: 35177287. DOI: 10.1016/j.suronc.2022.101712
    OpenUrlCrossRefPubMed
  59. ↵
    1. Markopoulos GS,
    2. Goussia A,
    3. Bali CD,
    4. Messinis T,
    5. Alexiou GA and
    6. Vartholomatos G
    : Resection margins assessment by intraoperative flow cytometry in pancreatic cancer. Ann Surg Oncol, 2022. PMID: 35303176. DOI: 10.1245/s10434-022-11645-7
    OpenUrlCrossRefPubMed
  60. ↵
    1. Shah MM and
    2. Kooby DA
    : Landmark Series: Importance of pancreatic resection margins response to comments to the editor-resection margins assessment by intraoperative flow cytometry in pancreatic cancer. Ann Surg Oncol, 2022. PMID: 35366701. DOI: 10.1245/s10434-022-11648-4
    OpenUrlCrossRefPubMed
  61. ↵
    1. Tao L,
    2. Su L,
    3. Yuan C,
    4. Ma Z,
    5. Zhang L,
    6. Bo S,
    7. Niu Y,
    8. Lu S and
    9. Xiu D
    : Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer. Cancer Manag Res 11: 7405-7425, 2019. PMID: 31496801. DOI: 10.2147/CMAR.S210332
    OpenUrlCrossRefPubMed
  62. ↵
    1. Grewal RK,
    2. Chetty M,
    3. Abayomi EA,
    4. Tomuleasa C and
    5. Fromm JR
    : Use of flow cytometry in the phenotypic diagnosis of Hodgkin’s lymphoma. Cytometry B Clin Cytom 96(2): 116-127, 2019. PMID: 30350336. DOI: 10.1002/cyto.b.21724
    OpenUrlCrossRefPubMed
  63. ↵
    1. Cherian S and
    2. Soma LA
    : How I diagnose minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma by flow cytometry. Am J Clin Pathol 155(1): 38-54, 2021. PMID: 33236071. DOI: 10.1093/ajcp/aqaa242
    OpenUrlCrossRefPubMed
    1. Wang JC,
    2. Deng XQ,
    3. Liu WP,
    4. Gao LM,
    5. Zhang WY,
    6. Yan JQ,
    7. Ye YX,
    8. Liu F and
    9. Zhao S
    : Comprehensive flow-cytometry-based immunophenotyping analysis for accurate diagnosis and management of extranodal NK/T cell lymphoma, nasal type. Cytometry B Clin Cytom 98(1): 28-35, 2020. PMID: 31313887. DOI: 10.1002/cyto.b.21838
    OpenUrlCrossRefPubMed
  64. ↵
    1. Au KLK,
    2. Latonas S,
    3. Shameli A,
    4. Auer I and
    5. Hahn C
    : Cerebrospinal fluid flow cytometry: Utility in central nervous system lymphoma diagnosis. Can J Neurol Sci 47(3): 382-388, 2020. PMID: 32228724. DOI: 10.1017/cjn.2020.22
    OpenUrlCrossRefPubMed
  65. ↵
    1. Huang S,
    2. Jin L,
    3. Yang J,
    4. Duan Y,
    5. Zhang M,
    6. Zhou C and
    7. Zhang YH
    : Characteristics of central nervous system (CNS) involvement in children with non-Hodgkin’s lymphoma (NHL) and the diagnostic value of CSF flow cytometry in CNS positive disease. Technol Cancer Res Treat 20: 15330338211016372, 2021. PMID: 34060372. DOI: 10.1177/15330338211016372
    OpenUrlCrossRefPubMed
  66. ↵
    1. Chen Z,
    2. Deng X,
    3. Ye Y,
    4. Zhang W,
    5. Liu W and
    6. Zhao S
    : Flow cytometry-assessed PD1/PDL1 status in tumor-infiltrating lymphocytes: a link with the prognosis of diffuse large B-cell lymphoma. Front Oncol 11: 687911, 2021. PMID: 34211855. DOI: 10.3389/fonc.2021.687911
    OpenUrlCrossRefPubMed
  67. ↵
    1. Marchetti A,
    2. Barberis M,
    3. Papotti M,
    4. Rossi G,
    5. Franco R,
    6. Malatesta S,
    7. Buttitta F,
    8. Ardizzoni A,
    9. Crinò L,
    10. Gridelli C,
    11. Taddei GL,
    12. Clemente C,
    13. Scagliotti G,
    14. Normanno N and
    15. Pinto C
    : ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol 9(10): 1470-1476, 2014. PMID: 25170637. DOI: 10.1097/JTO.0000000000000280
    OpenUrlCrossRefPubMed
  68. ↵
    1. Shang D,
    2. Liu Y,
    3. Xu X,
    4. Chen Z and
    5. Wang D
    : Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma. Cancer Cell Int 21(1): 465, 2021. PMID: 34488763. DOI: 10.1186/s12935-021-02169-3
    OpenUrlCrossRefPubMed
  69. ↵
    1. Borak S,
    2. Siegal GP,
    3. Reddy V,
    4. Jhala N and
    5. Jhala D
    : Metastatic inflammatory myofibroblastic tumor identified by EUS-FNA in mediastinal lymph nodes with ancillary FISH studies for ALK rearrangement. Diagn Cytopathol 40 Suppl 2: E118-E125, 2012. PMID: 21472870. DOI: 10.1002/dc.21663
    OpenUrlCrossRefPubMed
  70. ↵
    1. Guo Y,
    2. Peng Q,
    3. Wang Y,
    4. Li L,
    5. Yi X,
    6. Yan B,
    7. Zou M,
    8. Dai G,
    9. Guo P,
    10. Ma Q and
    11. Wu X
    : The application of DNA ploidy analysis in large-scale population screening for cervical cancer. Acta Cytol 65(5): 385-392, 2021. PMID: 34482310. DOI: 10.1159/000518052
    OpenUrlCrossRefPubMed
  71. ↵
    1. El-Gamal EM and
    2. Gouida MS
    : Flow cytometric study of cell cycle and DNA ploidy in bilharzial bladder cancer. Clin Lab 61(3-4): 211-218, 2015. PMID: 25974985. DOI: 10.7754/clin.lab.2014.140609
    OpenUrlCrossRefPubMed
  72. ↵
    1. Carloni S,
    2. Gallerani G,
    3. Tesei A,
    4. Scarpi E,
    5. Verdecchia GM,
    6. Virzì S,
    7. Fabbri F and
    8. Arienti C
    : DNA ploidy and S-phase fraction analysis in peritoneal carcinomatosis from ovarian cancer: correlation with clinical pathological factors and response to chemotherapy. Onco Targets Ther 10: 4657-4664, 2017. PMID: 29033584. DOI: 10.2147/OTT.S141117
    OpenUrlCrossRefPubMed
  73. ↵
    1. Zargoun IM,
    2. Bingle L and
    3. Speight PM
    : DNA ploidy and cell cycle protein expression in oral squamous cell carcinomas with and without lymph node metastases. J Oral Pathol Med 46(9): 738-743, 2017. PMID: 28135012. DOI: 10.1111/jop.12554
    OpenUrlCrossRefPubMed
  74. ↵
    1. Ghizoni JS,
    2. Sperandio M,
    3. Lock C and
    4. Odell EW
    : Image cytometry DNA ploidy analysis: Correlation between two semi-automated methods. Oral Dis 24(7): 1204-1208, 2018. PMID: 29757479. DOI: 10.1111/odi.12888
    OpenUrlCrossRefPubMed
  75. ↵
    1. Zaini ZM,
    2. McParland H,
    3. Møller H,
    4. Husband K and
    5. Odell EW
    : Predicting malignant progression in clinically high-risk lesions by DNA ploidy analysis and dysplasia grading. Sci Rep 8(1): 15874, 2018. PMID: 30367100. DOI: 10.1038/s41598-018-34165-5
    OpenUrlCrossRefPubMed
  76. ↵
    1. Sanger F,
    2. Nicklen S and
    3. Coulson AR
    : DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74(12): 5463-5467, 1977. PMID: 271968. DOI: 10.1073/pnas.74.12.5463
    OpenUrlAbstract/FREE Full Text
  77. ↵
    1. Pai JA and
    2. Satpathy AT
    : High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods 18(8): 881-892, 2021. PMID: 34282327. DOI: 10.1038/s41592-021-01201-8
    OpenUrlCrossRefPubMed
  78. ↵
    1. Lopez-Beltran A,
    2. Cimadamore A,
    3. Montironi R and
    4. Cheng L
    : Molecular pathology of urothelial carcinoma. Hum Pathol 113: 67-83, 2021. PMID: 33887300. DOI: 10.1016/j.humpath.2021.04.001
    OpenUrlCrossRefPubMed
  79. ↵
    1. Pisapia P,
    2. Pepe F,
    3. Iaccarino A,
    4. Sgariglia R,
    5. Nacchio M,
    6. Conticelli F,
    7. Salatiello M,
    8. Tufano R,
    9. Russo G,
    10. Gragnano G,
    11. Girolami I,
    12. Eccher A,
    13. Malapelle U and
    14. Troncone G
    : Next generation sequencing in cytopathology: focus on non-small cell lung cancer. Front Med (Lausanne) 8: 633923, 2021. PMID: 33644101. DOI: 10.3389/fmed.2021.633923
    OpenUrlCrossRefPubMed
  80. ↵
    1. Roy-Chowdhuri S,
    2. Pisapia P,
    3. Salto-Tellez M,
    4. Savic S,
    5. Nacchio M,
    6. de Biase D,
    7. Tallini G,
    8. Troncone G and
    9. Schmitt F
    : Invited review-next-generation sequencing: a modern tool in cytopathology. Virchows Arch 475(1): 3-11, 2019. PMID: 30877381. DOI: 10.1007/s00428-019-02559-z
    OpenUrlCrossRefPubMed
  81. ↵
    1. Conde E,
    2. Rojo F,
    3. Gómez J,
    4. Enguita AB,
    5. Abdulkader I,
    6. González A,
    7. Lozano D,
    8. Mancheño N,
    9. Salas C,
    10. Salido M,
    11. Salido-Ruiz E and
    12. de Álava E
    : Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. J Clin Pathol 75(3): 145-153, 2022. PMID: 33875457. DOI: 10.1136/jclinpath-2021-207490
    OpenUrlAbstract/FREE Full Text
  82. ↵
    1. Bera K,
    2. Schalper KA,
    3. Rimm DL,
    4. Velcheti V and
    5. Madabhushi A
    : Artificial intelligence in digital pathology – new tools for diagnosis and precision oncology. Nat Rev Clin Oncol 16(11): 703-715, 2019. PMID: 31399699. DOI: 10.1038/s41571-019-0252-y
    OpenUrlCrossRefPubMed
  83. ↵
    1. Chiu HY,
    2. Chao HS and
    3. Chen YM
    : Application of artificial intelligence in lung cancer. Cancers (Basel) 14(6): 1370, 2022. PMID: 35326521. DOI: 10.3390/cancers14061370
    OpenUrlCrossRefPubMed
    1. Zhao M,
    2. Yao S,
    3. Li Z,
    4. Wu L,
    5. Xu Z,
    6. Pan X,
    7. Lin H,
    8. Xu Y,
    9. Yang S,
    10. Zhang S,
    11. Li Y,
    12. Zhao K,
    13. Liang C and
    14. Liu Z
    : The Crohn’s-like lymphoid reaction density: a new artificial intelligence quantified prognostic immune index in colon cancer. Cancer Immunol Immunother 71(5): 1221-1231, 2022. PMID: 34642778. DOI: 10.1007/s00262-021-03079-z
    OpenUrlCrossRefPubMed
  84. ↵
    1. Fitzgerald J,
    2. Higgins D,
    3. Mazo Vargas C,
    4. Watson W,
    5. Mooney C,
    6. Rahman A,
    7. Aspell N,
    8. Connolly A,
    9. Aura Gonzalez C and
    10. Gallagher W
    : Future of biomarker evaluation in the realm of artificial intelligence algorithms: application in improved therapeutic stratification of patients with breast and prostate cancer. J Clin Pathol 74(7): 429-434, 2021. PMID: 34117103. DOI: 10.1136/jclinpath-2020-207351
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. van der Velden BHM,
    2. Kuijf HJ,
    3. Gilhuijs KGA and
    4. Viergever MA
    : Explainable artificial intelligence (XAI) in deep learning-based medical image analysis. Med Image Anal 79: 102470, 2022. PMID: 35576821. DOI: 10.1016/j.media.2022.102470
    OpenUrlCrossRefPubMed
  86. ↵
    1. Sanghvi AB,
    2. Allen EZ,
    3. Callenberg KM and
    4. Pantanowitz L
    : Performance of an artificial intelligence algorithm for reporting urine cytopathology. Cancer Cytopathol 127(10): 658-666, 2019. PMID: 31412169. DOI: 10.1002/cncy.22176
    OpenUrlCrossRefPubMed
  87. ↵
    1. Wang CW,
    2. Liou YA,
    3. Lin YJ,
    4. Chang CC,
    5. Chu PH,
    6. Lee YC,
    7. Wang CH and
    8. Chao TK
    : Artificial intelligence-assisted fast screening cervical high grade squamous intraepithelial lesion and squamous cell carcinoma diagnosis and treatment planning. Sci Rep 11(1): 16244, 2021. PMID: 34376717. DOI: 10.1038/s41598-021-95545-y
    OpenUrlCrossRefPubMed
  88. ↵
    1. Tang HP,
    2. Cai D,
    3. Kong YQ,
    4. Ye H,
    5. Ma ZX,
    6. Lv HS,
    7. Tuo LR,
    8. Pan QJ,
    9. Liu ZH and
    10. Han X
    : Cervical cytology screening facilitated by an artificial intelligence microscope: A preliminary study. Cancer Cytopathol 129(9): 693-700, 2021. PMID: 33826796. DOI: 10.1002/cncy.22425
    OpenUrlCrossRefPubMed
  89. ↵
    1. McAlpine ED and
    2. Michelow P
    : The cytopathologist’s role in developing and evaluating artificial intelligence in cytopathology practice. Cytopathology 31(5): 385-392, 2020. PMID: 31957101. DOI: 10.1111/cyt.12799
    OpenUrlCrossRefPubMed
  90. ↵
    1. Della Mea V
    : Prerecorded telemedicine. J Telemed Telecare 11(6): 276-284, 2005. PMID: 16168163. DOI: 10.1258/1357633054893382
    OpenUrlCrossRefPubMed
  91. ↵
    1. Lee ES,
    2. Kim IS,
    3. Choi JS,
    4. Yeom BW,
    5. Kim HK,
    6. Han JH,
    7. Lee MS and
    8. Leong AS
    : Accuracy and reproducibility of telecytology diagnosis of cervical smears. A tool for quality assurance programs. Am J Clin Pathol 119(3): 356-360, 2003. PMID: 12645336. DOI: 10.1309/7ytvag4xnr48t75h
    OpenUrlCrossRefPubMed
  92. ↵
    1. Dennis T,
    2. Start RD and
    3. Cross SS
    : The use of digital imaging, video conferencing, and telepathology in histopathology: a national survey. J Clin Pathol 58(3): 254-258, 2005. PMID: 15735155. DOI: 10.1136/jcp.2004.022012
    OpenUrlCrossRefPubMed
  93. ↵
    1. Sahin D,
    2. Hacisalihoglu UP and
    3. Kirimlioglu SH
    : Telecytology: Is it possible with smartphone images? Diagn Cytopathol 46(1): 40-46, 2018. PMID: 29115040. DOI: 10.1002/dc.23851
    OpenUrlCrossRefPubMed
  94. ↵
    1. Bonsembiante F,
    2. Bonfanti U,
    3. Cian F,
    4. Cavicchioli L,
    5. Zattoni B and
    6. Gelain ME
    : Diagnostic validation of a whole-slide imaging scanner in cytological samples: Diagnostic accuracy and comparison with light microscopy. Vet Pathol 56(3): 429-434, 2019. PMID: 30686128. DOI: 10.1177/0300985818825128
    OpenUrlCrossRefPubMed
  95. ↵
    1. Ma J,
    2. Yu J,
    3. Liu S,
    4. Chen L,
    5. Li X,
    6. Feng J,
    7. Chen Z,
    8. Zeng S,
    9. Liu X and
    10. Cheng S
    : PathSRGAN: Multi-supervised super-resolution for cytopathological images using generative adversarial network. IEEE Trans Med Imaging 39(9): 2920-2930, 2020. PMID: 32175859. DOI: 10.1109/TMI.2020.2980839
    OpenUrlCrossRefPubMed
  96. ↵
    1. Xu J,
    2. Xiang L,
    3. Liu Q,
    4. Gilmore H,
    5. Wu J,
    6. Tang J and
    7. Madabhushi A
    : Stacked sparse autoencoder (SSAE) for nuclei detection on breast cancer histopathology images. IEEE Trans Med Imaging 35(1): 119-130, 2016. PMID: 26208307. DOI: 10.1109/TMI.2015.2458702
    OpenUrlCrossRefPubMed
  97. ↵
    1. Zhang S,
    2. Zhou Y,
    3. Tang D,
    4. Ni M,
    5. Zheng J,
    6. Xu G,
    7. Peng C,
    8. Shen S,
    9. Zhan Q,
    10. Wang X,
    11. Hu D,
    12. Li WJ,
    13. Wang L,
    14. Lv Y and
    15. Zou X
    : A deep learning-based segmentation system for rapid onsite cytologic pathology evaluation of pancreatic masses: A retrospective, multicenter, diagnostic study. EBioMedicine 80: 104022, 2022. PMID: 35512608. DOI: 10.1016/j.ebiom.2022.104022
    OpenUrlCrossRefPubMed
  98. ↵
    1. Nojima S,
    2. Terayama K,
    3. Shimoura S,
    4. Hijiki S,
    5. Nonomura N,
    6. Morii E,
    7. Okuno Y and
    8. Fujita K
    : A deep learning system to diagnose the malignant potential of urothelial carcinoma cells in cytology specimens. Cancer Cytopathol 129(12): 984-995, 2021. PMID: 33979039. DOI: 10.1002/cncy.22443
    OpenUrlCrossRefPubMed
  99. ↵
    1. Liu W,
    2. Li C,
    3. Rahaman MM,
    4. Jiang T,
    5. Sun H,
    6. Wu X,
    7. Hu W,
    8. Chen H,
    9. Sun C,
    10. Yao Y and
    11. Grzegorzek M
    : Is the aspect ratio of cells important in deep learning? A robust comparison of deep learning methods for multi-scale cytopathology cell image classification: From convolutional neural networks to visual transformers. Comput Biol Med 141: 105026, 2022. PMID: 34801245. DOI: 10.1016/j.compbiomed.2021.105026
    OpenUrlCrossRefPubMed
  100. ↵
    1. Subramanian H and
    2. Subramanian S
    : Improving diagnosis through digital pathology: Proof-of-concept implementation using smart contracts and decentralized file storage. J Med Internet Res 24(3): e34207, 2022. PMID: 35343905. DOI: 10.2196/34207
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo: 37 (1)
In Vivo
Vol. 37, Issue 1
January-February 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 6 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques
CONGGAI HUANG, XING LUO, SHAOHUA WANG, YU WAN, JIEQIONG WANG, XIAOQIN TANG, CHRISTOPH SCHATZ, HUILING ZHANG, JOHANNES HAYBAECK, ZHIHUI YANG
In Vivo Jan 2023, 37 (1) 11-21; DOI: 10.21873/invivo.13050

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Minimally Invasive Cytopathology and Accurate Diagnosis: Technical Procedures and Ancillary Techniques
CONGGAI HUANG, XING LUO, SHAOHUA WANG, YU WAN, JIEQIONG WANG, XIAOQIN TANG, CHRISTOPH SCHATZ, HUILING ZHANG, JOHANNES HAYBAECK, ZHIHUI YANG
In Vivo Jan 2023, 37 (1) 11-21; DOI: 10.21873/invivo.13050
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Cytopathological Specimen Collection
    • Auxiliary Diagnostic
    • Conclusion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Molecular Mechanisms Involved in Craniosynostosis
  • Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal Cancer Treatment
Show more Review

Similar Articles

Keywords

  • Cytopathology
  • minimally invasive
  • accurate diagnosis
  • technical procedures
  • ancillary techniques
  • review
In Vivo

© 2023 In Vivo

Powered by HighWire